Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes.
Jason C ChangMichael D OffinChristina J FalconDavid N BrownBrian R LoomisFanli MengVasilisa A RudnevaHelen H WonSharon AmirJoseph MontecalvoPatrice DesmeulesKyuichi KadotaPrasad S AdusumilliValerie W RuschSarah TeedJoshua K SabariRyma BenayedKhedoudja NafaLaetitia BorsuBob T LiAlison M SchramMaria E ArcilaWilliam D TravisMarc LadanyiAlexander E DrilonNatasha RekhtmanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
This is the largest molecular study of IMAs to date, where we demonstrate the presence of a major oncogenic driver in nearly all cases. This study is the first to document more aggressive characteristics of NRG1-rearranged IMAs, ERBB2 as the third most common alteration, and a novel NRG2 fusion in these tumors. Comprehensive molecular testing of KRAS wild-type IMAs that includes fusion testing is essential, given the high prevalence of alterations with established and investigational targeted therapies in this subset.